Wells Fargo Maintains Argenx SE(ARGX.US) With Buy Rating, Maintains Target Price $741
TD Cowen Maintains Argenx SE(ARGX.US) With Buy Rating, Maintains Target Price $761
Analysts Offer Insights on Healthcare Companies: Milestone Scientific (MLSS), Neurocrine (NBIX) and Argenx Se (ARGX)
Citi Maintains Argenx SE(ARGX.US) With Buy Rating, Raises Target Price to $796
BofA Securities Maintains Argenx SE(ARGX.US) With Buy Rating, Maintains Target Price $774
TD Cowen Maintains Argenx SE(ARGX.US) With Buy Rating, Maintains Target Price $761
Argenx Is Maintained at Buy by Citigroup
Argenx Se (ARGX) Gets a Buy From TD Cowen
Bank of America Securities Sticks to Their Buy Rating for Argenx Se (ARGX)
UBS Maintains Argenx SE(ARGX.US) With Hold Rating, Maintains Target Price $620
Argenx Se (ARGX) Gets a Hold From UBS
Wedbush Maintains Argenx SE(ARGX.US) With Buy Rating, Maintains Target Price $715
Argenx Analyst Ratings
Wedbush Reiterates Outperform on Argenx, Maintains $715 Price Target
A Quick Look at Today's Ratings for Argenx SE(ARGX.US), With a Forecast Between $720 to $1,100
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Argenx Se (ARGX) and COMPASS Pathways (CMPS)
Argenx Analyst Ratings
Argenx Se (ARGX) Receives a Buy From Bank of America Securities
Wedbush Maintains Argenx SE(ARGX.US) With Buy Rating, Maintains Target Price $715
H.C. Wainwright Maintains Argenx SE(ARGX.US) With Buy Rating, Maintains Target Price $720